In this section : Rheumatology
Osteoarthritis of the Hand/Thumb
High Dose Steroid Pre-Treatment Checklist
Septic Arthritis
Back Pain
Osteoporosis
Gout
Giant Cell Arteritis
Polymyalgia Rheumatica
Rheumatoid Arthritis
Home | Articles | Rheumatology |
Rheumatoid Arthritis
Last updated 23rd May 2022
Diagnosis
- The diagnosis is essentially a clinical one, relying particularly in the early stages on the history and examination of the patient, with blood and imaging sometimes helping to confirm.
- By convention symptoms need to have persisted for more than 6 weeks to ensure that patients with self limiting forms of arthritis are not misdiagnosed as RA
- The American College of Rheumatology and European Alliance of Associations for Rheumtaology 2010 criteria can be applied to patients with definite synovitis in at least one joint
- Such patients can be classified with RA if they score 6 or more points
ARA Criteria for Identifying Early RA
Domain: Joint Involvement | |
1 large joint | 0 points |
2-10 large joints | 1 point |
1-3 small joints | 2 points |
4-10 small joints | 3 points |
>10 joints (including at least 1 small joint) | 5 points |
Domain: Serology | |
Not positive for either RF or anti-CCP | 0 points |
At least one of these tests are positive at low titer1 | 2 points |
At least one test is positive at high titer2 | 3 points |
Domain: Duration of synovitis | |
Less than 6 weeks | 0 points |
6 weeks or longer | 1 point |
Domain: Acute phase reactants | |
Neither CRP nor ESR is abnormal | 0 points |
Abnormal CRP or abnormal ESR | 1 point |
Note: Patients receive the highest point level they fulfil within each domain. For example, a patient with five small joints involved and four large joints involved scores 3 points.
1defined as more than the upper limit of normal but not higher than three times the upper limit of normal
2defined as more than three times the upper limit of normal
Identifying Active Synovitis
- RA is a deforming symmetrical polyarthritis affecting small joints of hands, feet and wrists
- An active synovitis identifies patients with an inflammatory arthritis who will benefit from Methotrexate.
- Inflammation manifests as pain, swelling, heat, stiffness and loss of function
- Occasionally joint will be red in RA but this should always raise suspicion of infection.
- Widespread synovitis may also cause systemic upset with malaise, fatigue, fever, sweats and weight loss
Investigations
- Xray hands and feet early in course of disease if persistent synovitis in these joints
- Check RF in suspected RA if found to have active synovitis
- Consider anti-CCP antibodies in suspected RA if RF negative
Management of Early RA
- Relief of symptoms
- Disease modification
- Refer all active synovitis to Rheumatology MDT asap
- Ensure patient has access to named member of Rheumatology MDT
Relief of Symptoms
- Commonly use paracetamol +/- NSAID
- Rx Paracetamol 1G qds to max of 4G in 24 hours but consider dose reduction if <50kg, chronically malnourished or alcoholic
- Rx ibuprofen 400-600mg tds after food, with PPI in those at high risk of GI adverse effects
Patients at Risk of Serious NSAID GI Effects
- Age ≥65 years
- History of peptic ulcer, perforation or GI bleeding
- Coprescription of drugs that increase risk of Gi adverse effects eg aspirin, warfarin, steroids, SSRIs
- Significant comorbidity eg cardiac, renal or liver failure, diabetes
- Need for prolonged NSAID use
- High dose NSAID eg Ibuprofen 2400mg/day
Disease Modification
- The earlier DMARDs are started the less long term joint destruction will occur
- Use Methotrexate as anchor drug. Other conventional DAMRDs which can be used are Hydroxychoroquine, Sulfasalazine and Leflunomide. A gradually tapered course of steroid may be given as bridge therapy while waiting for the DMARD action to kick in.
- Rx a combination of MTX with at least one other DMARD plus short term steroid – Prednisolone 7.5-10mg od for up to 3/12 – as first line therapy as soon as possible and ideally within 3/12 of onset of persistent symptoms
- If sustained and satisfactory disease control achieved then try cautious reduction in drug doses to levels which still maintain disease control.
- If combination therapy not appropriate or poorly tolerated and DMARD monotherapy started then place greater emphasis on fast escalation to clinically effective dose than on the choice of DMARD
Commonly Used DMARDS
- Methotrexate
- Sulfasalazine
- Hydroxychloroquine
- Leflunomide
Methotrexate
- First line for inflammatory arthritis.
- Initially 15mg/wk orally, increasing by 5mg every 2-4 weeks to 20 -30mg/wk. Can also give IM or SC
- Give folic acid 5mg orally the day after MTX.
- Side effects – myelosuppression, GI upset, rash, alopecia, stomatitis, pneumonitis, pulmonary fibrosis, hepatitis
Sulphasalazine
- Used for RA and peripheral arthritis in spondoarthropathy
- Initially 500mg od, increasing by 500mg at intervals of 1 week to a maximum of 40mg/kg daily in divided doses
- Side effects – nausea, myelosuppression, transaminitis, rash, diarrhoea, reversible male subfertility
Leflunomide
- Used for RA,
- 20mg od
- Side effects – diarrhoea, hypertension, myelosuppression, rash. Leflunomide has an entero-hepatic circulation and a very long half life. Use of Cholestyramine (see BNF) to eliminate the drug if withdrawn because of side effects
Hydroxychloroquine
- Used for RA, SLE
- Initially 400mg od, maintenance 200-400mg od
- Side effects – retinal toxicity, especially maculopathy. All require eye screening.
Cytokine Modulators (The Biologic and the Targeted Synthetic DMARDs)
- Highly effective but also highly expensive drugs that tend to be used after at least two conventional DMARDS have failed
- TNF alpha blockers – Etanercept, Infliximab, Adaluminab – are usually given in combination with Methotrexate
- Monoclonal antibodies – Rituximab (antiCD20 positive B cells) and Tociluzimab (anti IL-6) – are reserved for use if TNF alpha blockers fail. Both are usually given with Methotrexate.
- The JAK inhibitors – Tofacitinib, Baricitinib, Upadacitinib and Fligotinib
- Side effects of all these drugs include severe infections including reactivation of TB – important to alert Rheumatology team and stop at least temporarily if patient admitted with significant infection
Obsolete DMARDS: Only used where others fail
- Gold
- Penicillamine
- Azathioprine
- Cyclophosphamide
- Cyclosporin
Links
Content updated by Dr Richard Akintayo